Vanda Pharmaceuticals Conference Call Summary Company Overview - Vanda Pharmaceuticals is a global biopharmaceutical company focused on innovation to enhance people's happiness. The company has five approved products in the U.S. including: - **Fanapt**: An atypical antipsychotic for bipolar disorder and schizophrenia - **Hetlioz**: Approved for non-24-hour sleep-wake disorder and nighttime sleep disturbances in Smith-Magenis syndrome - **Ponvory**: Approved for multiple sclerosis - **NEREUS**: Recently approved for motion sickness - **Bysanti**: Approved for bipolar disorder and schizophrenia [2][3] Financial Position - Vanda ended the previous year with over **$260 million** in cash and no debt, indicating a strong financial position [3] - Revenue from Fanapt was **$117 million** in 2025, up from just under **$100 million** in 2024, with forecasts for **$150 million to $170 million** in 2026 [13][14] Product Pipeline and Growth Strategy - Vanda aims to grow and diversify revenue through existing products and new approvals, targeting **six approved products** by the end of the year [4] - Upcoming regulatory catalysts include: - **Imsidolimab**: BLA accepted for review with a PDUFA date of **December 12, 2026** [4] - **Bysanti**: Phase 3 study in major depressive disorder (MDD) with results expected by the end of 2026 [7][9] Bysanti's Market Potential - Bysanti's approval is expected to extend the revenue runway for Vanda's psychiatry portfolio, with potential label expansion for MDD [13][14] - The market size for schizophrenia and bipolar disorder is estimated at **10 million** patients, while MDD is approximately **20 million**, indicating significant growth potential [22] - Bysanti's pricing structure is expected to be more favorable than Fanapt, potentially leading to higher revenue [15][16] Commercialization Strategy - Vanda plans to leverage its existing psychiatry sales force for the launch of Bysanti in Q3 2026 [17][19] - The company anticipates that Bysanti could surpass Fanapt in demand due to its growth trajectory and market potential [20] NEREUS and Motion Sickness Market - NEREUS targets a market of **70 million** people in the U.S. experiencing motion sickness, with over **10 million** seeking treatment [51] - The product is expected to command premium pricing due to its favorable side effect profile compared to existing treatments [52] - Launch is anticipated in **mid-2026** [57] Research and Development Milestones - Vanda is focused on advancing its late-stage pipeline, including: - Phase 3 programs for NEREUS in GLP-1 market and Bysanti in MDD - Phase 3 for Fanapt long-acting injectable in schizophrenia [48] Regulatory Challenges - Vanda faced a Complete Response Letter (CRL) for NEREUS in gastroparesis but is pursuing a hearing with the FDA to present its case [78][80] - The company is optimistic about the potential for a favorable outcome based on recent legal victories [78] Future Outlook - Vanda's revenue guidance for 2026 is set at **$230 million to $260 million**, with specific targets for Fanapt, Ponvory, and Hetlioz [40][41] - The company is in an investment phase, expecting higher cash burn in 2026 due to product launches and pipeline investments [47] Conclusion - Vanda Pharmaceuticals is positioned for growth with a strong product pipeline and strategic focus on expanding its market presence in psychiatry and motion sickness. The company is navigating regulatory challenges while preparing for significant product launches in the near future.

Core Insights - Vanda Pharmaceuticals' shares rose following the FDA's approval of Bysanti, a new oral treatment for bipolar I disorder and schizophrenia, indicating potential market capture in these areas [1] - The FDA accepted Vanda's Biologics License Application for imsidolimab for Generalized Pustular Psoriasis, with a target action date of December 12 [2] Group 1: Bysanti Approval - The FDA's approval of Bysanti is expected to establish it as a first-line therapy for acute treatment of manic or mixed episodes associated with bipolar I disorder and schizophrenia in adults [5] - Bysanti is projected to be commercially available in Q3 2026, with marketing exclusivity lasting until 2044 [5] - Clinical studies showed Bysanti demonstrated bioequivalence to iloperidone, leveraging established efficacy and safety data from Vanda's previous drug, Fanapt, which had net product sales of $33.2 million in Q4 2025, reflecting a 25% year-over-year increase [6] Group 2: Imsidolimab for GPP - GPP is characterized by sudden eruptions of sterile, pus-filled blisters on the skin and systemic symptoms like fever and fatigue [3] - In pivotal studies, a single intravenous dose of imsidolimab led to 53% of patients achieving clear or almost clear skin at Week 4 compared to 13% on placebo [3] - Efficacy was maintained over a two-year maintenance period with no flares in the active treatment group [4] Group 3: Market Performance and Technical Analysis - Vanda's stock was up 4.53% at $8.53 during the publication time, aligning with a generally favorable market backdrop where the S&P 500 rose by 0.34% and Nasdaq gained 0.42% [7][10] - Currently, Vanda is trading 5.5% below its 20-day simple moving average and 10.2% below its 100-day simple moving average, indicating short-term weakness [8] - The stock carries a Buy Rating with an average price target of $18.11, with recent analyst upgrades raising targets to $24.00 and $14.00 [10]

Revenue Growth - Fanapt revenue growth of 24% was primarily driven by a 149% surge in new-to-brand prescriptions following the bipolar disorder commercial launch [1] - Management attributes accelerating Fanapt momentum to targeted commercial investments, including direct-to-consumer campaigns and a sales force expansion to approximately 300 representatives [1] Product Performance - HETLIOZ revenue declined 7% due to generic competition, though the product has retained the majority of market share after three years of generic entry [1] - The approval of Nereus for motion sickness addresses a significant unmet need for the estimated 25% to 30% of U.S. adults experiencing symptoms during travel [1] - Strategic positioning of PONVORY is shifting toward psoriasis and ulcerative colitis to leverage its rapid lymphocyte recovery profile over competing S1P modulators [1] Financial Impact - The company recorded a one-time non-cash income tax charge of $113.7 million related to a valuation allowance against deferred tax assets based on projected pretax income [1]

Core Insights - Vanda Pharmaceuticals reported a 9% increase in total revenues for 2025, reaching $216.1 million, primarily driven by growth in Fanapt sales, despite a decline in Hetlioz revenue due to generic competition [2][4] Financial Performance - Full-year net product sales for Hetlioz decreased by 7% to $71.4 million, attributed to lower volume and pricing pressures from U.S. generic competition [1] - Fanapt net product sales increased by 24% to $117.3 million, supported by a 28% rise in total prescriptions and a 149% increase in new-to-brand prescriptions [3] - The company reported a full-year net loss of $220.5 million for 2025, significantly higher than the $18.9 million loss in 2024, largely due to a one-time, non-cash tax charge [5][7] Quarterly Performance - Fourth-quarter total revenues were $57.2 million, an 8% year-over-year increase, with Fanapt sales rising by 25% to $33.2 million [6] - Hetlioz's fourth-quarter net product sales fell by 18% to $16.4 million, while Ponvory's sales increased by 17% to $7.6 million [7] Operating Expenses - Operating expenses rose to $367.3 million in 2025 from $239.4 million in 2024, driven by increased SG&A expenses related to commercial launches and higher R&D costs [8] Cash Position - As of December 31, 2025, cash, cash equivalents, and marketable securities totaled $263.8 million, down $110.8 million from the previous year [9] Pipeline and Regulatory Updates - The FDA approved Nereus for motion-induced vomiting, marking a significant regulatory achievement for the company [11] - Vanda plans to initiate a phase III program for tradipitant in vomiting associated with GLP-1 agonists in the first half of 2026 [12] - The NDA for Bysanti is under FDA review with a PDUFA date of February 21, 2026 [13] - The company submitted the BLA for imsidolimab for generalized pustular psoriasis in Q4 2025 [14] Commercial Strategy - Vanda expanded its commercial infrastructure, increasing the Fanapt sales force from about 160 to 300 representatives by the end of 2025 [15] - For 2026, the company expects total revenues from currently marketed products to be between $230 million and $260 million, with a continued decline in Hetlioz sales anticipated [16] Future Guidance - The company does not provide cash guidance for 2026 but expects cash burn to exceed 2025 levels [17] - Vanda is also pursuing clinical development programs for Ponvory in psoriasis and ulcerative colitis, with ongoing studies for Bysanti and VQW-765 [19]

Financial Data and Key Metrics Changes - Total revenues for the full year 2025 were $216.1 million, a 9% increase compared to $198.8 million for 2024 [18] - Net loss for the full year 2025 was $220.5 million, compared to a net loss of $18.9 million for 2024, primarily due to a one-time, non-cash income tax charge [21][22] - Operating expenses for the full year 2025 were $367.3 million, an increase from $239.4 million in 2024 [24] Business Line Data and Key Metrics Changes - Fanapt net product sales were $117.3 million for 2025, a 24% increase from $94.3 million in 2024, driven by a 28% rise in total prescriptions and a 149% surge in new-to-brand prescriptions [5][19] - Hetlioz net product sales were $71.4 million for 2025, a 7% decrease from $76.7 million in 2024, impacted by generic competition [20] - Ponvory net product sales were $27.4 million for 2025, a 2% decrease from $27.8 million in 2024 [21] Market Data and Key Metrics Changes - Fanapt was one of the fastest-growing atypical antipsychotics in the market throughout 2025, with total prescriptions increasing by 36% in Q4 2025 compared to Q4 2024 [37] - The total addressable market for the antipsychotic category was estimated at approximately $20 billion in 2025 [7] - The global long-acting injectable antipsychotic market is projected to be in the $6 billion-$7 billion range for 2025, with strong growth expected [12] Company Strategy and Development Direction - The company plans to initiate a dedicated phase III program for Nereus in the first half of 2026, targeting the GLP-1 agonist market [7] - Vanda aims to strengthen its psychiatry franchise with the anticipated approval of Bysanti for bipolar I disorder and schizophrenia, with a PDUFA target action date of February 21, 2026 [8][17] - The company is committed to delivering innovative therapies and long-term value for patients and shareholders [17] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the commercial launch of Nereus and the potential for significant market opportunities in motion sickness [6] - The company expects total revenues of $230 million-$260 million from current marketed products in 2026, indicating continued growth [17][40] - Management highlighted the importance of strategic investments in commercial infrastructure to support long-term market leadership [26] Other Important Information - The company recorded a valuation allowance of $113.7 million against all deferred tax assets, which is a one-time, non-cash charge [22][24] - Cash, cash equivalents, and marketable securities as of December 31, 2025, were $263.8 million, a decrease of $110.8 million compared to the previous year [26] Q&A Session Summary Question: Can you characterize any FDA communication on outstanding issues related to Bysanti? - Management remains optimistic for an on-time approval and will provide more details on the launch strategy once commercial supplies are ready [48] Question: What is the expected commercial infrastructure for imsidolimab? - A small specialty sales force will be key for addressing the rare dermatological condition associated with imsidolimab [50] Question: Can you provide details on promotional activities for Fanapt and Bysanti? - Current direct-to-consumer campaigns focus on Fanapt and Ponvory, with plans for a dedicated campaign for Bysanti upon its launch [52] Question: When will Nereus be commercially available? - Commercial materials are expected to be ready by late Q2 or early Q3 2026 [54] Question: What is the expected pricing for Nereus? - Pricing is not yet communicated, but it is expected to be at a premium compared to existing treatments for motion sickness [71]

Financial Data and Key Metrics Changes - Total revenues for the full year 2025 were $216.1 million, a 9% increase compared to $198.8 million for 2024 [18] - Net product sales for Fanapt were $117.3 million, a 24% increase from $94.3 million in 2024 [18] - The company recorded a net loss of $220.5 million for 2025, compared to a net loss of $18.9 million in 2024 [21] - Operating expenses for 2025 were $367.3 million, up from $239.4 million in 2024 [24] Business Line Data and Key Metrics Changes - Fanapt's total prescriptions increased by 28% in 2025 compared to 2024 [19] - HETLIOZ net product sales were $71.4 million for 2025, a 7% decrease from $76.7 million in 2024 due to generic competition [20] - Ponvory net product sales were $27.4 million for 2025, a 2% decrease from $27.8 million in 2024 [21] Market Data and Key Metrics Changes - The total addressable market for the antipsychotic category is estimated at approximately $20 billion in 2025 [7] - The long-acting injectable antipsychotic market is projected to be in the $6 billion-$7 billion range for 2025 [12] Company Strategy and Development Direction - The company plans to initiate a dedicated phase III program for Nereus in the first half of 2026, targeting the GLP-1 agonist market [7] - Vanda aims to strengthen its psychiatric franchise with the anticipated approval of Bysanti for bipolar I disorder and schizophrenia [17] - The company is focused on expanding its commercial infrastructure and brand visibility through targeted sponsorships and marketing programs [26][36] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the commercial launch of Nereus and the potential for significant market opportunities in motion sickness [6] - The company expects total revenues of $230 million-$260 million from current marketed products in 2026, indicating continued growth [40] - Management highlighted the importance of addressing unmet medical needs in major depressive disorder and social anxiety disorder through innovative therapies [10][12] Other Important Information - The company recorded a one-time, non-cash income tax charge of $113.7 million for the valuation allowance against deferred tax assets [22] - Cash, cash equivalents, and marketable securities as of December 31, 2025, were $263.8 million, a decrease of $110.8 million compared to the previous year [26] Q&A Session Summary Question: Can you provide updates on Bysanti's FDA review and commercial strategy? - Management indicated optimism for an on-time approval and mentioned that commercialization would begin in Q3 2026 if approved [48] Question: What is the expected commercial infrastructure for Imsidolimab? - A small specialty sales force will be dedicated to marketing Imsidolimab, focusing on dermatologists and advocacy organizations [50] Question: Can you elaborate on promotional activities for Fanapt and Bysanti? - Current direct-to-consumer campaigns focus on Fanapt and Ponvory, with plans for a dedicated campaign for Bysanti upon its launch [52] Question: When will Nereus be commercially available? - Nereus is expected to be commercially available by late Q2 or early Q3 2026 [54] Question: What is the pricing strategy for Nereus? - While a specific price has not been communicated, it is expected to be at a premium compared to existing treatments for motion sickness [71]

Financial Data and Key Metrics Changes - Total revenues for the full year 2025 were $216.1 million, a 9% increase compared to $198.8 million for 2024 [16] - Net loss for the full year 2025 was $220.5 million, compared to a net loss of $18.9 million for 2024, primarily due to a one-time, non-cash income tax charge [18][19] - Operating expenses for the full year 2025 were $367.3 million, an increase from $239.4 million in 2024 [21] Business Line Data and Key Metrics Changes - Fanapt net product sales increased by 24% to $117.3 million in 2025, driven by a 28% rise in total prescriptions and a 149% surge in new-to-brand prescriptions [5][17] - HETLIOZ net product sales decreased by 7% to $71.4 million in 2025 due to generic competition [17] - Ponvory net product sales were $27.4 million, a slight decrease of 2% compared to 2024 [18] Market Data and Key Metrics Changes - Fanapt was one of the fastest-growing atypical antipsychotics in the market throughout 2025, with total prescriptions increasing by 36% in Q4 2025 compared to Q4 2024 [31] - The global long-acting injectable antipsychotic market is projected to be valued between $6 billion and $7 billion in 2025, with strong growth expected [11] Company Strategy and Development Direction - The company plans to launch Nereus for motion sickness, which was approved in late 2025, targeting a substantial market opportunity [6] - Vanda is preparing for the commercial launch of Bysanti, with a focus on transitioning patients from Fanapt [41] - The company aims to strengthen its psychiatric franchise with ongoing clinical development programs and potential new product approvals [15] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the commercial potential of Nereus and the upcoming launch of Bysanti, anticipating continued revenue growth from existing products [15][34] - The company expects total revenues from marketed products in 2026 to be between $230 million and $260 million, indicating a growth of approximately 13% compared to 2025 [34] Other Important Information - Cash, cash equivalents, and marketable securities as of December 31, 2025, were $263.8 million, a decrease of $110.8 million compared to the previous year [23] - The company recorded a valuation allowance against all net deferred tax assets, resulting in a non-cash income tax expense of $113.7 million for 2025 [21] Q&A Session Summary Question: Can you characterize any FDA communication on Bysanti? - Management remains optimistic for an on-time approval and will provide more details on the launch strategy if approved [41][42] Question: What is the expected commercial infrastructure for Imsidolimab? - A small specialty sales force will be key for addressing the rare dermatological condition [44] Question: What promotional activities are planned for Fanapt and Bysanti? - A direct-to-consumer campaign for Fanapt and Ponvory is expected to continue, with a dedicated campaign for Bysanti planned if approved [45] Question: When will Nereus be commercially available? - Commercial materials are expected to be ready by late Q2 or early Q3 2026 [46] Question: What is the pricing strategy for Nereus? - Pricing is expected to be premium compared to existing treatments for motion sickness [65] Question: Will the phase 3 trial for tradipitant follow the same design as phase 2? - Yes, the design will be similar, using a high upfront dose of Wegovy [68]

Company Overview - Vanda Pharmaceuticals is a leading global biopharmaceutical company focused on innovating to enhance people's happiness [2] - The company employs an innovation-led strategy with a successful track record in developing and commercializing therapies over decades [2] Product Portfolio - Vanda has a robust commercial portfolio anchored by four FDA-approved brands: Fanapt (atypical antipsychotic), HETLIOZ (for two orphan sleep disorders), PONVORY (for multiple sclerosis), and the recently approved NEREUS (for motion-induced vomiting) [3] - The company maintains a strong debt-free balance sheet, providing substantial capital for R&D and commercial activities [3] Pipeline and Growth Potential - Vanda has a late-stage growth pipeline with numerous high-potential programs targeting significant unmet needs in billion-dollar markets [4] - The company is positioned for imminent regulatory catalysts, including the recently approved NEREUS [4]

Vanda Pharmaceuticals FY Conference Summary Company Overview - Vanda Pharmaceuticals is a global biopharmaceutical company focused on innovative therapies with a strong commercial portfolio anchored by four FDA-approved brands: Fanapt, Hetlioz, Ponvory, and Nereus [2][3] Core Products and Pipeline - **Fanapt**: An atypical antipsychotic approved for bipolar I disorder and schizophrenia. A long-acting injectable formulation is in phase three for schizophrenia, and a program for hypertension has been initiated [4][5] - **Hetlioz**: Approved for non-24-hour sleep-wake disorder and other sleep disturbances. It is at the regulatory stage for insomnia and jet lag disorder [6][7] - **Ponvory**: Approved for relapsing forms of multiple sclerosis, with ongoing phase three programs for psoriasis and ulcerative colitis [6][7] - **Nereus**: Recently approved for motion sickness, with potential applications in GLP-1 induced nausea and vomiting, and gastroparesis [6][7][10] Financial Performance - For Q3 2025, Vanda reported revenue of $56.3 million, with contributions from Fanapt ($31 million), Hetlioz ($18 million), and Ponvory ($7 million). The company expects total revenue for 2025 to be between $210 million and $230 million [21][22] Strategic Focus - The company aims to grow and diversify revenue by expanding existing products and introducing new ones, targeting six commercial products by the end of 2026 [3][4] - Upcoming regulatory catalysts include Bysanti's PDUFA date on February 21, 2026, and the initiation of phase three programs for GLP-1 induced vomiting [7][10] Market Opportunities - **Nereus**: The motion sickness market has approximately 30% of adults in the U.S. experiencing symptoms, translating to a potential patient population of around 12 million. The GLP-1 market, valued at over $50 billion, presents a significant opportunity for Nereus as an adjunct treatment [11][12][35] - **Bysanti**: Expected to extend the psychiatry portfolio, especially with a potential indication for major depressive disorder (MDD), which could open treatment options for an additional 20 million patients [15][31] Commercialization Strategy - Vanda has a robust sales force of around 300 reps, primarily targeting psychiatrists, but plans to expand efforts to include primary care physicians for Bysanti [26][28] - The company anticipates a transition strategy from Fanapt to Bysanti, leveraging existing resources to maintain revenue streams post-Fanapt's expected loss of exclusivity around 2027 [28][29] R&D Milestones - Nereus's approval for motion sickness was a significant milestone, with a commercial launch expected in the second half of 2026. The company is also pursuing additional indications for its products [7][10] - Imsidolimab, targeting generalized pustular psoriasis, is under priority review with a potential launch in summer 2026 [17][37] Conclusion - Vanda Pharmaceuticals is positioned for significant growth with a strong pipeline and strategic focus on expanding its product offerings. The upcoming regulatory milestones and market opportunities in motion sickness and the GLP-1 space are key drivers for future revenue growth [39]

Vanda Pharmaceuticals Conference Call Summary Company Overview - Vanda Pharmaceuticals is a leading global biopharmaceutical company focused on innovating to enhance people's happiness [2][3] - The company has three commercialized products: - **Fanapt**: Approved for bipolar disorder and schizophrenia in the U.S. - **Hetlioz**: Approved for non-24-hour sleep-wake disorder and nighttime sleep disturbances in Smith-Magenis Syndrome in both adults and pediatric populations, with approvals in Europe as well [2][3] - **Ponvory**: Approved for multiple sclerosis, acquired from Johnson & Johnson at the end of 2023 [3] Financial Position - As of Q3 2025, Vanda has approximately $294 million in cash and no debt [3] - 2025 revenue guidance is set between $210 million and $230 million, with Q3 2025 revenue reported at $56.3 million [12][13] Product Pipeline and Regulatory Updates - **Fanapt**: - Pursuing FDA approval for **Basanti**, the active metabolite of Fanapt, with a PDUFA target action date of February 21, 2026 [3][10] - Phase three program for major depressive disorder (MDD) expected to yield results in 2026 [4][10] - Long-acting injectable formulation of Fanapt is in phase three trials [11] - **Hetlioz**: - Re-review of the jet lag supplemental new drug application (SNDA) with an FDA decision expected by January 7, 2026 [4][10] - Pursuing additional indications for Hetlioz, including jet lag and maintaining market share against generics [6][7] - **Ponvory**: - Commercial launch is progressing well, with increased patient demand noted [7][8] - Ongoing phase three programs for psoriasis and ulcerative colitis [12] - **Tradipitant**: - Upcoming PDUFA date for motion sickness on December 30, 2025 [9][12] - Phase two study for nausea in patients taking GLP-1 medications is underway, with results expected in Q4 2025 [9][46] - **Imsidolumab**: - Biologics License Application (BLA) for generalized pustular psoriasis (GPP) expected to be submitted by the end of the year [10] Strategic Focus - Vanda aims to grow revenue organically through existing products and through potential business development opportunities [5] - Focus on increasing access and affordability for patients while engaging directly with consumers [5] Market Dynamics and Competitive Landscape - The antipsychotic market is evolving with new entrants like Kobenphy, which presents both opportunities and challenges [25][26] - The treatment landscape remains promotionally sensitive, with a high switch rate among patients seeking effective medications [27][28] Upcoming Milestones and Expectations - The company is optimistic about the upcoming PDUFA dates and the potential for positive results in ongoing trials [20][32] - The MDD trial is seen as a significant opportunity, with a large addressable market [34][35] - The motion sickness and jet lag markets are expected to be driven by consumer demand, with potential insurance coverage as well [38][40] Conclusion - Vanda Pharmaceuticals is well-positioned with a strong financial foundation and a robust pipeline of products and regulatory submissions. The company is focused on maximizing the potential of its existing products while navigating the competitive landscape and addressing unmet medical needs in various therapeutic areas.